SML0107
Pemirolast potassium
≥98% (HPLC)
Synonym(s):
9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one potassium salt; BMY 26517
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C10H7N6O·K
CAS Number:
Molecular Weight:
266.30
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
light yellow to green-yellow
solubility
H2O: ≥18 mg/mL
originator
Bristol-Myers Squibb
storage temp.
2-8°C
SMILES string
[K+].CC1=CC=CN2C(=O)C(=CN=C12)c3nnn[n-]3
InChI
1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1
InChI key
NMMVKSMGBDRONO-UHFFFAOYSA-N
Biochem/physiol Actions
Pemirolast potassium is a histamine H1 antagonist and mast cell stabilizer; Inhibitor of chemical mediator release from tissue mast cells; antiallergic agent
Pemirolast potassium is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent. It Inhibits chemical mediator release from tissue mast cells and has recently also been shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves. It has been used for the treatment of allergic conjunctivitis prophylaxis of for pulmonary hypersensitivity reactions to drugs such as paclitaxel
Features and Benefits
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Teresa Magone et al.
Cornea, 25(3), 364-367 (2006-04-25)
To report a case of peripheral interstitial keratitis in a patient with mastocytosis. Clinical case description and immunohistologic examination of biopsied ocular tissue. A 22-year-old woman with biopsy-proven urticaria pigmentosa, a subset of mastocytosis, presented with an active peripheral interstitial
Petrus Gous et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 20(2), 139-150 (2004-05-01)
To compare efficacy and safety between twice-daily and four-times-daily regimens of pemirolast 0.1% in allergic conjunctivitis patients. This investigator-masked trial recruited 169 patients, with a positive skin prick test, +2 itching and hyperemia. Patients were randomized to two times daily
Yoshinori Itoh et al.
Neuropharmacology, 46(6), 888-894 (2004-03-23)
The effects of anti-allergic agents on the hypersensitivity reactions to paclitaxel, an anti-cancer agent, were examined in rats. Intravenous injection of paclitaxel (15 mg/kg) caused a marked extravasation of plasma protein in lungs and a transient decrease in arterial partial
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML0107-10MG | 04061833027141 |
| SML0107-50MG | 04061833027158 |